Hung Trinh: Natera Announces Enrollment of First Patients in SAGITTARIUS
Hung Trinh, Senior Director of Business Development at OBiO Tech, posted on LinkedIn:
“Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer.
SAGITTARIUS is Natera’s first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancer.
Approximately 700-900 patients expected to be enrolled across more than 20 sites.
AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients with colon cancer.
SAGITTARIUS includes collaborations with 9 partners in 5 countries in Europe, and a network of 26 clinical centers in Italy, Spain, and Germany.
‘The enrollment of the first patients in SAGITTARIUS represents a significant milestone in a trial that has the potential to transform treatment approaches for colorectal cancer,’ said Silvia Marsoni, MD, PhD, head of the precision oncology unit at IFOM ETS and scientific coordinator of the SAGITTARIUS Project.
‘The trial aims to move beyond the traditional one-size-fits-all, post-surgical standard of care with chemotherapy by introducing a truly personalized treatment approach tailored to each patient,’ said Adham Jurdi, MD, senior medical director of oncology at Natera.
‘Signatera-positive patients will receive adjuvant therapies matched to their specific mutational profiles. Additionally, we are optimistic that the study will generate evidence to support the de-escalation of chemotherapy for Signatera-negative patients.’
Clara Montagut, MD, PhD, head of the gastrointestinal cancer unit at Hospital del Mar in Barcelona, Spain, and principal investigator of the SAGITTARIUS clinical trial, further emphasized the study’s innovative goals, noting, ‘We aim to anticipate the use of therapies tailored to the molecular landscape of the patient’s tumor, including immunotherapy and targeted therapies with proven efficacy in the metastatic setting within the adjuvant treatment context. To our knowledge, SAGITTARIUS is currently the only trial pursuing this approach in the field of liquid biopsy research.'”
Hung Trinh is the Senior Director of Business Development at OBiO Tech. He previously served as Director of Process Development and Manufacturing Science and Technology at Vyriad and Associate Director of Downstream Process Development at Genezen. With experience in vaccine development, spanning both pre-clinical and clinical studies, Trinh has worked with various CDMOs focusing on lentiviral vector production and CAR-T cell manufacturing.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023